~8 spots leftby Apr 2026

Improved Sleep for Obesity and Diabetes Risk Reduction

EH
Overseen byErin Hanlon, Ph.D.
Age: 18 - 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: University of Chicago
No Placebo Group

Trial Summary

What is the purpose of this trial?

The goal of this study is to identify an intervention that improves sleep health and consequently metabolic health by examining whether sleep extension or enforced regularity in short sleepers will have beneficial effects on diabetes and obesity risk.

Research Team

EH

Erin Hanlon, Ph.D.

Principal Investigator

University of Chicago

Eligibility Criteria

This trial is for African American adults aged 21-50 who are overweight with a BMI of 25 to 30 and usually sleep less than 7 hours at night. Participants should have the potential to sleep more if they had the time.

Inclusion Criteria

I am between 22 and 50 years old.
I usually sleep less than 7 hours a night.
I am African American.
See 1 more

Treatment Details

Interventions

  • Sleep Extension (Behavioral Intervention)
  • Sleep Regularity (Behavioral Intervention)
Trial OverviewThe study is testing two approaches to improve sleep health: one group will try sleeping longer (sleep extension), while another will focus on keeping a consistent sleep schedule (sleep regularity). The aim is to see if these methods can lower diabetes and obesity risk.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Sleep RegularityExperimental Treatment1 Intervention
Participants in the sleep regularity group will have consistent bedtimes (within 30min).
Group II: Sleep ExtensionExperimental Treatment1 Intervention
Participants that are in the sleep extension group will have their time in bed extended by 2 hours. This can include going to bed earlier and/or waking up later.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Chicago

Lead Sponsor

Trials
1,086
Recruited
844,000+
Pete Salzmann profile image

Pete Salzmann

University of Chicago

Chief Executive Officer since 2018

MD from University of Chicago’s Pritzker School of Medicine, MBA from Stanford University’s Graduate School of Business

Anh Nguyen profile image

Anh Nguyen

University of Chicago

Chief Medical Officer

MD from Rutgers New Jersey Medical School, MBA from University of Chicago